The spectrum of monogenic autoinflammatory syndromes: understanding disease mechanisms and use of targeted therapies.
about
Early detection of sensorineural hearing loss in Muckle-Wells-syndromeBlocking interleukin-1 in rheumatic diseasesCanakinumab (ACZ885, a fully human IgG1 anti-IL-1β mAb) induces sustained remission in pediatric patients with cryopyrin-associated periodic syndrome (CAPS)A novel mutation of IL1RN in the deficiency of interleukin-1 receptor antagonist syndrome: description of two unrelated cases from Brazil.Clinical characteristics in subjects with NLRP3 V198M diagnosed at a single UK center and a review of the literature.Monogenic autoinflammatory diseases: concept and clinical manifestations.Canakinumab in patients with cryopyrin-associated periodic syndrome: an update for clinicians.Canakinumab for treatment of cryopyrin-associated periodic syndrome.The emerging role of interleukin-1β in autoinflammatory diseases.Setting up TRAPS.The emerging role of interleukin-1β in autoinflammatory diseases.Bimodal immune activation in psoriasis.Pyogenic arthritis, pyoderma gangrenosum, and acne (PAPA) syndrome: differential diagnosis of septic arthritis by regular detection of exceedingly high synovial cell counts.[Efficacy and safety analysis of off-label treatment with biologics in autoinflammatory diseases : Experiences from a German registry (GRAID2)].[Cryopyrin-associated periodic syndrome].[Autoinflammatory syndromes/fever syndromes].Risk factors for severe Muckle-Wells syndrome.[Comments on the pathogenesis of Behçet's disease. A key to understanding new therapies?].Anti-interleukin 1 treatment in secondary amyloidosis associated with autoinflammatory diseases.
P2860
Q27303524-75A5A212-B65B-4807-9506-5711D45374EAQ34822708-6AFFA07B-1CC1-4583-8983-92AD7468C531Q35620372-585090E6-24B4-4CDF-B4DB-286BC0D7A3F3Q36296299-FDD9BB70-604A-4901-91D5-C36EA14D66CBQ36903004-86DEF85D-6C20-4C81-A05E-1C58516CDCA6Q37162157-FC50606A-2BE6-489D-9AB4-FCC6949AFC7CQ37331996-A066FF69-E0BC-4A5A-85DA-66C7ECD91C06Q37800938-5279A8C0-C200-4C25-8A11-11C9B4C14702Q37802305-9929EAA5-995B-4195-A2B1-A9DBB96B5677Q37834022-E4F53FB6-C994-44B4-8866-137440BE4090Q37897494-9DDD58CA-E375-4E59-9516-B3A6796E69DEQ38151778-032D90FE-52E2-4DA9-AF34-2AEE6F58CA98Q39157509-15A864EC-95A9-42CA-91C8-787DBFA0637FQ40053587-D3C7CF54-0D01-4A05-A160-7B8DBFAFE7A3Q40289375-5DE89CD6-FD6E-4922-B010-5BD238C947E8Q40326095-5868CE4F-974A-4485-8E21-2EE68B0CEBFFQ50436945-6419B456-43A4-4295-B5D7-B4A882DA242DQ52887889-33276337-3374-4E1C-82B6-EAC61D3B8651Q53279630-C51DAD1C-12C9-4C59-8612-CC8E0D14F6DC
P2860
The spectrum of monogenic autoinflammatory syndromes: understanding disease mechanisms and use of targeted therapies.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on July 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
The spectrum of monogenic auto ...... and use of targeted therapies.
@en
The spectrum of monogenic auto ...... and use of targeted therapies.
@nl
type
label
The spectrum of monogenic auto ...... and use of targeted therapies.
@en
The spectrum of monogenic auto ...... and use of targeted therapies.
@nl
prefLabel
The spectrum of monogenic auto ...... and use of targeted therapies.
@en
The spectrum of monogenic auto ...... and use of targeted therapies.
@nl
P2860
P1476
The spectrum of monogenic auto ...... and use of targeted therapies.
@en
P2093
Rachel L Glaser
Raphaela Goldbach-Mansky
P2860
P2888
P304
P356
10.1007/S11882-008-0047-1
P577
2008-07-01T00:00:00Z